Athersys has filed a patent for a method of treating viral-induced acute respiratory distress syndrome (ARDS) by administering multipotent adult progenitor cells (MAPCs) to the affected subject. The cells are non-embryonic stem cells that have a broad differentiation potential and extended replication capacity. The method can be used to treat ARDS caused by various viruses, including SARS, MERS, and SARS-CoV-2. The cells used in the treatment have specific characteristics, such as expressing telomerase and/or oct4, not being transformed or tumorigenic, and having a normal karyotype. GlobalData’s report on Athersys gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Athersys, human telomerase RT biomarker was a key innovation area identified from patents. Athersys's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230181651A1) describes a method for treating viral-induced acute respiratory distress syndrome (ARDS). The method involves administering specific cells to a subject with ARDS in order to effectively treat the condition. These cells, referred to as cells (I), are non-embryonic stem cells that have undergone at least 10-40 cell doublings in culture. They express telomerase and/or oct4, are not transformed or tumorigenic, and have a normal karyotype.
The method outlined in the patent claims can be used to treat viral-induced ARDS by administering cells (I) to the subject. These cells have specific characteristics, including the expression of telomerase and/or oct4, and the ability to differentiate into at least two of the endodermal, ectodermal, and mesodermal cell types. The cells (I) are non-embryonic stem cells that have undergone multiple cell doublings in culture, ensuring their stability and effectiveness.
The patent also specifies that the cells (I) can be of human origin and derived from bone marrow. They can be allogeneic, meaning they can be sourced from a donor other than the subject. The method is applicable to various viruses that induce ARDS, including Betacoronavirus, which includes severe acute respiratory syndrome (SARS), Middle East Respiratory Syndrome (MERS), and severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Other viruses mentioned in the patent include influenza, herpes simplex virus, cytomegalovirus, rhinoviruses, respiratory syncytial virus, parainfluenza virus, human metapneumovirus, and adenovirus.
The subject of the treatment method described in the patent is specified to be human, and the route of administration is intravenous. This suggests that the cells (I) are administered directly into the bloodstream of the subject.
Overall, this patent outlines a method for treating viral-induced ARDS by administering specific cells to the subject. These cells have undergone multiple cell doublings in culture, express telomerase and/or oct4, and have the ability to differentiate into different cell types. The method is applicable to various viruses, including Betacoronavirus, and is intended for use in human subjects via intravenous administration.
To know more about GlobalData’s detailed insights on Athersys, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
